Gerald P Mcmahon

US Patent:

6350754, Feb 26, 2002

Filed:

Jan 12, 2000

Appl. No.:

09/482198

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 31404

US Classification:

514275, 514373, 514379, 514403, 514406, 514415, 514418, 514444, 514447, 514469, 544242, 544297, 544322, 544333, 544334, 544335, 548207, 548209, 548241, 5483601, 548469, 548470, 548483, 548486, 549 49, 549 58, 549396, 549407

Abstract:

The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

US Patent:

6376529, Apr 23, 2002

Filed:

Sep 24, 1999

Appl. No.:

09/405244

Inventors:

Peng Cho Tang - Moraga CA 94556
Gerald McMahon - San Francisco CA 94109
Ken Lipson - San Mateo CA 94402

International Classification:

A61K 31404

US Classification:

514414, 548455, 548460

Abstract:

The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.

US Patent:

6395734, May 28, 2002

Filed:

May 28, 1999

Appl. No.:

09/322297

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 314045

US Classification:

5142352, 514414, 544144, 548468

Abstract:

The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

US Patent:

6469032, Oct 22, 2002

Filed:

Jan 22, 2001

Appl. No.:

09/765619

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 314015

US Classification:

514339, 514359, 514361, 514362, 514363, 514364, 514365, 514372, 514374, 514378, 514380, 514383, 514397, 514406, 514414, 514416

Abstract:

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

US Patent:

6486185, Nov 26, 2002

Filed:

Nov 12, 1998

Appl. No.:

09/191458

Inventors:

Gerald McMahon - Kenwood CA
Peng Cho Tang - Moraga CA
Li Sun - Foster City CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

C07D40314

US Classification:

514359, 514361, 514397, 548125, 548143, 548202, 548250

Abstract:

The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

US Patent:

6506763, Jan 14, 2003

Filed:

Jul 30, 2001

Appl. No.:

09/916331

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 31505

US Classification:

514274, 514314, 514339, 514411, 514418, 514455, 544315, 5462777, 546152, 548486, 548455, 548440

Abstract:

The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related disorders such as cancer.

US Patent:

6569868, May 27, 2003

Filed:

Jul 6, 2001

Appl. No.:

09/899550

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA
G. David Harris - San Francisco CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 31435

US Classification:

514300, 546113, 5483121, 514397

Abstract:

The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

US Patent:

6596772, Jul 22, 2003

Filed:

Aug 25, 2000

Appl. No.:

09/645879

Inventors:

Ping Huang - Mountain View CA
Chung Chen Wei - Foster City CA
Peng Cho Tang - Moraga CA
Chris Liang - Sunnyvale CA
John Ramphal - Union City CA
Bahija Jallal - Menlo Park CA
John Biltz - Newark CA
Sharon Li - Los Altos CA
Matt Mattson - Santa Clara CA
Gerald McMahon - Kenwood CA
Marcel Koenig - Burlingame CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

A61K 3105

US Classification:

514602, 514613, 514715, 514730, 544106, 544162, 544170, 564 80, 564 84, 564100, 564123, 564430, 568 21, 568 38, 568579, 568608

Abstract:

The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.